Orgenesis Inc. Free Cash Flow Margin

Free Cash Flow Margin of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow Margin growth rates and interactive chart. Free cash flow margin or Free cash flow-to-sales is a performance ratio that measures operating cash flows after deduction of capital expenditures (free cash flow) relative to sales. Free cash flows (FCF) is an important metric in assessing a company's financial condition and determining its intrinsic valuation. FCF/sales is tracked over time and can be compared to a company's historical record or to peers. Free cash flow is useful because it takes out non-cash items out of earnings and only looks at the underlying operating cash coming in and out of a business minus the necessary capital expenditures.


Highlights and Quick Summary

  • Annual Free Cash Flow Margin for 2020 was -1039.78% (a 60.43% increase from previous year)
  • Annual Free Cash Flow Margin for 2019 was -648.11% (a 455.32% increase from previous year)
  • Annual Free Cash Flow Margin for 2018 was -116.71% (a 2.51% increase from previous year)
  • Twelve month Free Cash Flow Margin ending September 29, 2021 was -242.94% (a -20.64% decrease compared to previous quarter)
  • Twelve month trailing Free Cash Flow Margin decreased by -76.64% year-over-year
Trailing Free Cash Flow Margin for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
-242.94% -306.14% -467.88% -1039.78%
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow Margin of Orgenesis Inc.

Most recent Free Cash Flow Marginof ORGS including historical data for past 10 years.

Interactive Chart of Free Cash Flow Margin of Orgenesis Inc.

Orgenesis Inc. Free Cash Flow Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -1039.78%
2019 -648.11%
2018 -116.71%
2017 -37.99%
2016 -59.14%
2015 -124.01%
2014 0.0%
2013 0.0%
2012 0.0%

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.